Classification and Toxicities of Vascular Disrupting Agents
- 1 January 2011
- journal article
- review article
- Published by Elsevier BV in Clinical Lung Cancer
- Vol. 12 (1), 18-25
- https://doi.org/10.3816/clc.2011.n.002
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Vascular targeted therapies in oncologyCell and tissue research, 2008
- IFN-β-Dependent Inhibition of Tumor Growth by the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA)Journal of Interferon & Cytokine Research, 2008
- Vascular disrupting agents in clinical developmentBritish Journal of Cancer, 2007
- 5,6-Dimethylxanthenone-4-Acetic Acid in the Treatment of Refractory Tumors: a Phase I Safety Study of a Vascular Disrupting AgentClinical Cancer Research, 2006
- Activation of Tumor-Associated Macrophages by the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid Induces an Effective CD8+ T-Cell–Mediated Antitumor Immune Response in Murine Models of Lung Cancer and MesotheliomaCancer Research, 2005
- Vascular Targeting Agents as Cancer TherapeuticsClinical Cancer Research, 2004
- Antivascular therapy of cancer: DMXAAThe Lancet Oncology, 2003
- 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA): a New Biological Response Modifier for Cancer TherapyInvestigational New Drugs, 2002
- Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acidsJournal of Medicinal Chemistry, 1991
- Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinomaBritish Journal of Cancer, 1989